Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57] NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03] 0.87[0.67; 1.12]HYDRA (Hernandez-Cardenas), 2021, Mobarak S (DISCOVER), 2021, NIH NIAID ACTT-1, 2020330%2,359moderatenot evaluable deathsdetailed resultsCAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] Gonzalez (HCQ), 2020 0.33 [0.06; 1.78] Gonzalez (IVER), 2020 0.83 [0.23; 3.02] HYCOVID, 2020 0.54 [0.21; 1.40] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kirti, 2021 0.12 [0.01; 2.36] Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] ORCHID, 2020 1.07 [0.54; 2.11] ProPAC-COVID, 2021 0.08 [0.00; 8.65] TEACH, 2020 1.07 [0.34; 3.37] 0.81[0.63; 1.05]CAP-China (Wang et al.), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Mobarak S (DISCOVER), 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, ProPAC-COVID, 2021, TEACH, 20201120%3,821moderatelow deaths (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] 0.66[0.46; 0.95]HYDRA (Hernandez-Cardenas), 2021, NIH NIAID ACTT-1, 2020232%1,276moderatenot evaluable clinical deteriorationdetailed resultsCAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] TEACH, 2020 1.80 [0.62; 5.21] 1.10[0.65; 1.88]CAP-China (Wang et al.), 2020, TEACH, 202029%365lownot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] ORCHID, 2020 1.02 [0.73; 1.42] 1.24[1.10; 1.40]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 202030%1,778moderatenot evaluable clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] ORCHID, 2020 1.02 [0.73; 1.42] 1.06[0.79; 1.42]CAP-China (Wang et al.), 2020, ORCHID, 202020%715lownot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76] ORCHID, 2020 0.97 [0.69; 1.37] 1.21[0.97; 1.51]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020317%1,777moderatenot evaluable clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] Kirti, 2021 0.90 [0.77; 1.06] ORCHID, 2020 1.16 [0.84; 1.61] 0.95[0.82; 1.09]CAP-China (Wang et al.), 2020, Kirti, 2021, ORCHID, 202030%827moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] ORCHID, 2020 0.97 [0.69; 1.36] Shinkai, 2021 1.40 [0.91; 2.15] 1.22[1.09; 1.37]CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, Shinkai, 202150%2,148moderatenot evaluable death or ventilationdetailed resultsGonzalez (HCQ), 2020 0.69 [0.22; 2.21] Gonzalez (IVER), 2020 0.89 [0.30; 2.64] HYCOVID, 2020 1.12 [0.45; 2.79] ORCHID, 2020 1.13 [0.60; 2.13] 1.01[0.65; 1.57]Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, ORCHID, 202040%867moderatenot evaluable hospital dischargedetailed resultsGonzalez (HCQ), 2020 1.38 [0.46; 4.16] Gonzalez (IVER), 2020 0.71 [0.15; 3.40] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] Kirti, 2021 1.20 [0.73; 1.98] 1.07[0.82; 1.40]Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 202140%469moderatenot evaluable mechanical ventilationdetailed resultsKirti, 2021 0.20 [0.00; 8.69] Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19] 1.33[0.49; 3.59]Kirti, 2021, Mobarak S (DISCOVER), 202127%1,195moderatenot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] 0.92[0.77; 1.09]Chaccour, 202010%24NAnot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Kirti, 2021 0.80 [0.43; 1.50] 0.91[0.77; 1.08]Chaccour, 2020, Kirti, 202120%136lownot evaluable ICU admissiondetailed resultsKirti, 2021 0.90 [0.30; 2.70] ProPAC-COVID, 2021 1.24 [0.26; 5.80] 1.00[0.41; 2.45]Kirti, 2021, ProPAC-COVID, 202120%229moderatenot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable recoverydetailed resultsMobarak S (DISCOVER), 2021 0.97 [0.89; 1.05] 0.97[0.89; 1.05]Mobarak S (DISCOVER), 202110%1,083NAnot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] ORCHID, 2020 1.26 [0.56; 2.84] Shinkai, 2021 2.80 [0.14; 56.95] 0.75[0.59; 0.96]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, Shinkai, 202140%1,931moderatenot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] ORCHID, 2020 1.42 [0.87; 2.34] Shinkai, 2021 19.54 [7.77; 49.11] TEACH, 2020 1.16 [0.55; 2.42] 2.44[0.69; 8.69]Chaccour, 2020, ORCHID, 2020, Shinkai, 2021, TEACH, 2020489%787moderatenot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.62[0.23; 1.64]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.58[0.34; 0.97]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202026%1,296moderatenot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.97[0.48; 1.93]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296lownot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.82[0.20; 3.29]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-04 00:06 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons